MA40532A - Inhibiteurs de glycosidases - Google Patents

Inhibiteurs de glycosidases

Info

Publication number
MA40532A
MA40532A MA040532A MA40532A MA40532A MA 40532 A MA40532 A MA 40532A MA 040532 A MA040532 A MA 040532A MA 40532 A MA40532 A MA 40532A MA 40532 A MA40532 A MA 40532A
Authority
MA
Morocco
Prior art keywords
glycosidase inhibitors
glycosidase
inhibitors
Prior art date
Application number
MA040532A
Other languages
English (en)
Inventor
Awadut Gajendra Giri
Santosh S Kulkarni
Anna Quattropani
Original Assignee
Asceneuron Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54065334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40532(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asceneuron Sa filed Critical Asceneuron Sa
Publication of MA40532A publication Critical patent/MA40532A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
MA040532A 2014-08-28 2015-08-27 Inhibiteurs de glycosidases MA40532A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2766MU2014 2014-08-28

Publications (1)

Publication Number Publication Date
MA40532A true MA40532A (fr) 2021-04-28

Family

ID=54065334

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053944A MA53944A (fr) 2014-08-28 2015-08-27 Inhibiteurs de la glycosidase
MA040532A MA40532A (fr) 2014-08-28 2015-08-27 Inhibiteurs de glycosidases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053944A MA53944A (fr) 2014-08-28 2015-08-27 Inhibiteurs de la glycosidase

Country Status (16)

Country Link
US (3) US10336775B2 (fr)
EP (2) EP3186243B1 (fr)
JP (2) JP6563017B2 (fr)
KR (1) KR102043337B1 (fr)
CN (1) CN107108601B (fr)
AU (2) AU2015308437C1 (fr)
BR (1) BR112017003658B1 (fr)
CA (1) CA2958966C (fr)
EA (1) EA201790271A1 (fr)
ES (1) ES2893289T3 (fr)
IL (1) IL250642B (fr)
MA (2) MA53944A (fr)
MX (1) MX2017002670A (fr)
SG (1) SG11201701315VA (fr)
WO (1) WO2016030443A1 (fr)
ZA (1) ZA201701299B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790271A1 (ru) 2014-08-28 2017-08-31 Асенейрон Са Ингибиторы гликозидазы
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
MX2018010199A (es) * 2016-02-25 2019-05-20 Asceneuron S A Proceso para la separacion de enantiomeros de derivados de piperazina.
AU2017222958B2 (en) * 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
AU2017222964B2 (en) * 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
CN109071526B (zh) 2016-02-25 2023-02-28 阿森纽荣股份公司 哌嗪衍生物的酸加成盐
CN110300752A (zh) * 2016-12-16 2019-10-01 詹森药业有限公司 单环oga抑制剂化合物
US20190359609A1 (en) 2016-12-16 2019-11-28 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
TWI654978B (zh) * 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
US20200048267A1 (en) * 2017-02-06 2020-02-13 Janssen Pharmaceutica Nv Oga inhibitor compounds
MX2019010085A (es) * 2017-02-24 2019-11-21 Asceneuron S A Inhibidores de la glicosidasa de sulfoximina.
EP3585790A1 (fr) * 2017-02-27 2020-01-01 Janssen Pharmaceutica NV Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
AR111693A1 (es) 2017-05-25 2019-08-07 Lilly Co Eli Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
WO2019037861A1 (fr) 2017-08-24 2019-02-28 Asceneuron S.A. Inhibiteurs de glycosidases annelés
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
CA3103910A1 (fr) * 2018-06-20 2019-12-26 Janssen Pharmaceutica Nv Composes inhibiteurs d'oga
AU2019291097A1 (en) * 2018-06-20 2020-12-17 Janssen Pharmaceutica Nv OGA inhibitor compounds
TW202016093A (zh) * 2018-06-20 2020-05-01 比利時商健生藥品公司 Ｏｇａ抑制劑化合物
WO2019243530A1 (fr) * 2018-06-20 2019-12-26 Janssen Pharmaceutica Nv Composés inhibiteurs d'oga
EP3810136A1 (fr) * 2018-06-20 2021-04-28 Janssen Pharmaceutica NV Composés inhibiteurs d'oga
ES2927355T3 (es) * 2018-06-21 2022-11-04 Janssen Pharmaceutica Nv Compuestos inhibidores de OGA
AU2019291101A1 (en) * 2018-06-21 2021-01-07 Janssen Pharmaceutica Nv OGA inhibitor compounds
TWI726329B (zh) 2018-06-22 2021-05-01 美商美國禮來大藥廠 2,3-二氫呋喃并[2,3-b]吡啶化合物
CN108863980A (zh) * 2018-07-05 2018-11-23 浙江工业大学 一种合成1-(5-苯并噻唑基)乙酮的方法
EP3829634A1 (fr) 2018-07-31 2021-06-09 Eli Lilly and Company Polythérapie
HUE063226T2 (hu) 2018-08-22 2024-01-28 Asceneuron Sa Glikozidáz inhibitorokként használható piperazinszármazékok szukcinát és fumarát savaddíciós sói
WO2020039028A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de tétrahydro-benzoazépine glycosidase
WO2020039027A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de pyrrolidine glycosidase
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
US20220106305A1 (en) * 2019-02-04 2022-04-07 Biogen Ma Inc. Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
WO2020169804A1 (fr) 2019-02-22 2020-08-27 Asceneuron Sa Inhibiteurs de glycosidases fusionnés
WO2021094312A1 (fr) 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Composés inhibiteurs d'oga contenant de la pyrrolidine et de la bicyclohétéroaryle
CA3160367A1 (fr) 2019-12-18 2021-06-24 Jose Manuel Bartolome-Nebreda Composes inhibiteurs d'oga
WO2021123291A1 (fr) 2019-12-18 2021-06-24 Janssen Pharmaceutica Nv Composés inhibiteurs d'oga
AU2020409728A1 (en) 2019-12-18 2022-08-11 Janssen Pharmaceutica Nv OGA inhibitor compounds
IL309862A (en) 2021-07-05 2024-02-01 Ferrer Int Medicines that include glycosidase inhibitors

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1311316A (fr) 1961-04-12 1962-12-07 Science Union Et Compagnie Soc Nouveaux dérivés de la pipérazine et leurs préparations
NL127996C (fr) 1963-11-19
US3485757A (en) 1964-11-23 1969-12-23 Atomic Energy Commission Thermoelectric composition comprising doped bismuth telluride,silicon and boron
DE1595923A1 (de) 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung
GB1165283A (en) * 1967-01-17 1969-09-24 Science Union & Cie New Purine Derivatives and processes for prepararing them
US4600025A (en) 1982-11-18 1986-07-15 Grigg Ronald E Smoking products comprising nicotine substitutes
CA2133077A1 (fr) 1992-04-15 1993-10-28 Raymond Baker Composes azacycliques
IL118768A (en) 1995-07-12 2000-10-31 Akzo Nobel Nv Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation
TW504510B (en) 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
CA2282390A1 (fr) 1997-04-17 1998-10-22 Yukio Fujisawa Composition thermogenique et composes thermogeniques a base de benzazepine
EP1025097B1 (fr) 1997-10-24 2005-04-27 Neurogen Corporation Piperazines de 1-(2-naphtyle) et de 1-(2-azanaphtyle)-4-(1-phenylmethyle)en tant que ligands pour le sous-type du recepteur de la dopamine d 4
KR20040012851A (ko) * 2001-05-22 2004-02-11 뉴로젠 코포레이션 멜라닌 농축성 호르몬 수용체 리간드: 치환된1-벤질-4-아릴 피페라진 유사체
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US6921821B2 (en) 2002-06-12 2005-07-26 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
NZ566367A (en) 2002-07-05 2009-04-30 Targacept Inc N-Aryl diazaspiracyclic compounds capable of affecting nicotinic cholinergic receptors and methods of preparation and use thereof
BR0306309A (pt) 2002-09-09 2004-10-19 Janssen Pharmaceutica Nv Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1
JP2006523692A (ja) 2003-04-18 2006-10-19 イーライ リリー アンド カンパニー ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物
JP4552854B2 (ja) 2003-05-21 2010-09-29 萬有製薬株式会社 ２−アミノキノリン誘導体
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
US7253168B2 (en) 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
US20080287375A1 (en) 2005-03-01 2008-11-20 Simon Fraser University Selective Glycosidase Inhibitors, Methods of Making Inhibitors, and Uses Thereof
EP1904466A1 (fr) 2005-07-08 2008-04-02 Novo Nordisk A/S Activateurs de dicycloalkylurée glucokinase
CN101454292A (zh) 2006-03-31 2009-06-10 阿斯利康(瑞典)有限公司 双环苯并咪唑化合物及其作为代谢型谷氨酸受体增效剂的用途
US20090306126A1 (en) 2006-05-22 2009-12-10 Astrazeneca Ab Indole Derivatives
US20080051387A1 (en) 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
WO2008012623A1 (fr) 2006-07-25 2008-01-31 Pfizer Products Inc. Composés de benzimidazolyle constituant des potentialisateurs du sous-type de récepteur de glutamate mglur2
AU2007291870B2 (en) 2006-08-31 2012-12-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
WO2009011904A1 (fr) 2007-07-19 2009-01-22 Renovis, Inc. Composés utiles comme modulateurs de la faah et utilisation de ceux-ci
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
CA2709784A1 (fr) 2007-12-21 2009-07-09 University Of Rochester Procede permettant de modifier la duree de vie d'organismes eucaryotes
US20110053982A1 (en) 2008-04-17 2011-03-03 Pfizer Inc. Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
WO2009127948A1 (fr) 2008-04-17 2009-10-22 Pfizer Inc. Composés aryl carboxamides à 5 éléments de 4-[3-(aryloxy)benzylidène]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2009154132A1 (fr) 2008-06-19 2009-12-23 萬有製薬株式会社 Dérivé de spirodiamine-diarylcétoxime
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
WO2010021381A1 (fr) 2008-08-22 2010-02-25 武田薬品工業株式会社 Dérivé hétérocyclique fusionné et son utilisation
WO2010022517A1 (fr) 2008-08-29 2010-03-04 Saint Mary's University Utilisation de gluconacetobacter et utilisation réduite d'engrais azoté pour améliorer la production de betteraves
EP2336104A4 (fr) 2008-09-02 2012-01-25 Nissan Chemical Ind Ltd Dérivé halogénoalkylsulfonanilide ortho-substitué et herbicide
TW201030007A (en) 2009-02-06 2010-08-16 Gruenenthal Gmbh Substituted spiro-amides as b1r modulators
WO2010101949A1 (fr) 2009-03-02 2010-09-10 Sirtris Pharmaceuticals, Inc. Quinoléines substituées en 8 et analogues associés utilisés comme modulateurs de sirtuine
US20100240720A1 (en) 2009-03-20 2010-09-23 Burnham Institute For Medical Research Allosteric jnk inhibitors
WO2010108268A1 (fr) 2009-03-23 2010-09-30 Merck Frosst Canada Ltd. Composés hétérocycliques inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
JP2010270034A (ja) 2009-05-20 2010-12-02 Sumitomo Chemical Co Ltd アミド化合物並びにその植物病害防除用途
CA2765678A1 (fr) 2009-06-22 2010-12-29 Christopher Blackburn Acides hydroxamiques substitues et leurs utilisations
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
JP2013537233A (ja) 2010-09-17 2013-09-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 脂肪酸合成酵素阻害剤
WO2012061927A1 (fr) 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Inhibiteurs sélectifs de glycosidase et utilisations de ceux-ci
WO2012061972A1 (fr) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Inhibiteurs sélectifs de la glycosidase et ses utilisations
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2589164T3 (es) 2010-12-23 2016-11-10 Alectos Therapeutics Inc. Inhibidores selectivos de glucosidasas y usos de los mismos
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
WO2012124744A1 (fr) 2011-03-14 2012-09-20 大正製薬株式会社 Composé hétérocyclique condensé contenant de l'azote
ES2568603T3 (es) 2011-08-25 2016-05-03 Merck Patent Gmbh Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasas
WO2013066729A1 (fr) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Aminopyrimidinones en tant qu'inhibiteurs de kinases associées au récepteur de l'interleukine
WO2014023723A1 (fr) 2012-08-08 2014-02-13 Novartis Ag Azines substituées comme pesticides
WO2014032187A1 (fr) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Inhibiteurs de glycosidases et leurs utilisations
CA2899088C (fr) 2013-03-14 2022-12-20 Merck Patent Gmbh Composes de thiazole et d'oxazole en tant qu'inhibiteurs de glycosidase
CN103435606A (zh) 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
CN106061973B (zh) 2013-12-05 2019-07-09 辉瑞公司 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡嗪基和吡咯并[2,3-d]吡啶基丙烯酰胺
EP2913330A1 (fr) 2014-02-27 2015-09-02 Laboratoire Biodim Dérivés condensés d'imidazole utiles comme produits pharmaceutiques
US9932345B2 (en) 2014-04-23 2018-04-03 Dart Neuroscience (Cayman) Ltd. Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors
EA201790271A1 (ru) 2014-08-28 2017-08-31 Асенейрон Са Ингибиторы гликозидазы
WO2017001661A1 (fr) 2015-07-02 2017-01-05 Janssen Sciences Ireland Uc Composés antibactériens
JP6872541B2 (ja) 2015-11-02 2021-05-19 ヤンセン ファーマシューティカ エヌ．ベー． ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
WO2017087863A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
HUE056356T2 (hu) 2015-11-25 2022-02-28 Lieber Inst Inc Tetrahidro-8H-pirido[1,2-a]pirazin-8-on vegyületek, mint COMT inhibitorok neurodegeneratív rendellenességek kezelésére
US10913733B2 (en) 2015-12-18 2021-02-09 Alectos Therapeutics Inc. Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof
AU2017222958B2 (en) 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
MX2018010199A (es) 2016-02-25 2019-05-20 Asceneuron S A Proceso para la separacion de enantiomeros de derivados de piperazina.
CN109071526B (zh) 2016-02-25 2023-02-28 阿森纽荣股份公司 哌嗪衍生物的酸加成盐
AU2017222964B2 (en) 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
US11186564B2 (en) 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
US20190359609A1 (en) 2016-12-16 2019-11-28 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
CN110300752A (zh) 2016-12-16 2019-10-01 詹森药业有限公司 单环oga抑制剂化合物
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
US20200048267A1 (en) 2017-02-06 2020-02-13 Janssen Pharmaceutica Nv Oga inhibitor compounds
MX2019010085A (es) 2017-02-24 2019-11-21 Asceneuron S A Inhibidores de la glicosidasa de sulfoximina.
EP3585790A1 (fr) 2017-02-27 2020-01-01 Janssen Pharmaceutica NV Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
AR111693A1 (es) 2017-05-25 2019-08-07 Lilly Co Eli Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga

Also Published As

Publication number Publication date
MX2017002670A (es) 2017-10-31
JP6563017B2 (ja) 2019-08-21
IL250642A0 (en) 2017-04-30
ES2893289T3 (es) 2022-02-08
KR102043337B1 (ko) 2019-11-11
AU2015308437A1 (en) 2017-03-16
BR112017003658A2 (pt) 2017-12-05
US20220411440A1 (en) 2022-12-29
AU2019200339A1 (en) 2019-02-07
KR20170042790A (ko) 2017-04-19
IL250642B (en) 2020-07-30
CN107108601B (zh) 2021-08-20
US10336775B2 (en) 2019-07-02
CN107108601A (zh) 2017-08-29
EP3868752A1 (fr) 2021-08-25
BR112017003658B1 (pt) 2022-12-06
MA53944A (fr) 2021-08-25
SG11201701315VA (en) 2017-03-30
AU2019200339B2 (en) 2019-12-19
AU2015308437B2 (en) 2018-10-18
CA2958966C (fr) 2020-01-14
CA2958966A1 (fr) 2016-03-03
EP3186243B1 (fr) 2021-07-21
JP2019206554A (ja) 2019-12-05
EA201790271A1 (ru) 2017-08-31
AU2015308437C9 (en) 2020-07-16
JP2017525775A (ja) 2017-09-07
AU2015308437C1 (en) 2020-11-05
US20190367533A1 (en) 2019-12-05
US20170298082A1 (en) 2017-10-19
US11046712B2 (en) 2021-06-29
ZA201701299B (en) 2024-01-31
WO2016030443A1 (fr) 2016-03-03
EP3186243A1 (fr) 2017-07-05

Similar Documents

Publication Publication Date Title
MA40532A (fr) Inhibiteurs de glycosidases
MA43677A (fr) Inhibiteurs de glycosidases
MA43680A (fr) Inhibiteurs de glycosidases
DK3442972T3 (da) Bromdomænehæmmere
DK3204359T3 (da) Tetrahydroisoquinolinderivater
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3191487T3 (da) Spirocykliske cathepsin-c-inhibitorer
DK3231803T3 (da) Dihydroindolizinonderivat
BR112016030730A2 (pt) Composto
DK3131898T3 (da) Fluoroalkylfluorenderivativer
DK3143018T3 (da) Carboxamidderivater
DK3481826T3 (da) Tyrosinkinaseinhibitorer
MA43165A (fr) Inhibiteurs de ret
ITUA20162175A1 (it) Stimolatore clitorideo
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
UA32461S (uk) Лінійка
DOS2015000101S (es) Protector de cabeza
TH1501006052A (th) สารยับยั้ง bacei
DK3119744T3 (da) 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamidderivater
UA29057S (uk) Шафка
TH1601001495A (th) สารประกอบ n-แอซิลอิมิโนเฮเทอโรไซคลิค